Vertex Pharmaceuticals Incorporated

VRTX • Biotechnology

$519.20

▲ +4.55 (+0.88%)

Precio actual

ResultadosÚltimo reporte: 30 jun 2026

PERFIL FAVORABLEAtractivaConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Alta calidad del negocio, con crecimiento y flujo de caja que respaldan el caso. La valoración todavía importa, pero el historial de ratios es favorable.

Capitalización

$131.61B

Crecimiento

18.7%

Flujo de caja

4/5

Tendencia

Mostly stable

Evidencia

Márgenes estables o en mejora · 32.7%Crecimiento positivo de ingresos · 12.6%Flujo de caja libre positivo · 12.49Flujo de caja libre consistente · 4/5Nivel de deuda manejable · 0.21

Datos financieros hasta: 30 jun 2026, 12:00 a.m. UTCÚltima actualización de earnings: 30 jun 2026, 12:00 a.m. UTCÚltima actualización del perfil: 6 ago 2026, 12:09 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$519.20

Change0.88%

Shares Out255.70M

Market Cap$131.61B

Enterprise Value$123.76B

52W Range362.50 - 533.67

Beta0.29

P/E29.88

P/S10.42

P/B6.50

P/FCF34.67

EV/Sales9.80

Price$519.20

Change0.88%

Shares Out255.70M

Market Cap$131.61B

Enterprise Value$123.76B

52W Range362.50 - 533.67

Beta0.29

P/E29.88

P/S10.42

P/B6.50

P/FCF34.67

EV/Sales9.80

EV/EBITDA23.62

EV/FCF32.60

Earnings Yield3.35%

FCF Yield2.88%

Dividend Yield0.00%

Gross Margin85.03%

Oper. Margin39.43%

Profit Margin32.74%

Debt/Eq0.21

Current Ratio2.90

Quick Ratio2.46

Revenue 5Y18.70%

Target$573.50

Target Upside10.46%

Target Median$601.50

Target Range350.00 - 665.00

Volume1.13M

Avg Volume1.49M

EPS Surprise0.23

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

90/100

Fortaleza financiera

Deuda, caja, estabilidad

95/100

Potencial de crecimiento

Ingresos y expansión

87/100

Atractivo del precio

Barata o cara hoy

38/100

Por qué este puntaje▼

Márgenes estables o en mejora · 32.7%Crecimiento positivo de ingresos · 12.6%Flujo de caja libre positivo · 12.49Flujo de caja libre consistente · 4/5Nivel de deuda manejable · 0.21Liquidez saludable · 2.9

Analyst view

Analyst sentiment and price target

VRTX

Analyst sentiment

Based on 56 analyst votes · 2026-10-20

92/100

Bullish

Hold

Bearish

Precio objetivo

2026-08-06

Bajo

$350.00

Promedio

$552.93

Mediana

$576.00

Alto

$617.00

Resumen de la compañía

IPO: 7/24/1991

Industria: Biotechnology

P/B i: 6.50

Deuda / Patrimonio i: 0.21

Margen operativo: 39.43%

Margen neto: 32.74%

ROE i: -

ROIC: -

Salud financiera

Puntaje19 / 20

Deuda / Patrimonio: 0.21

Ratio corriente: 2.90

Ratio rápido: 2.46

Estado: Strong

Transacciones internas

Actividad reciente de ejecutivos e insiders

Sachdev Amit

Transacción: 07/21/2026

COMPRA

Cambio

+8,251

Precio

Not reported

Presentación

07/23/2026

Tipo

COMPRA

Tatsis Ourania

Transacción: 07/21/2026

COMPRA

Cambio

+8,251

Precio

Not reported

Presentación

07/23/2026

Tipo

COMPRA

Garber Alan M

Transacción: 07/15/2026

COMPRA

Cambio

—

Precio

Not reported

Presentación

07/17/2026

Tipo

COMPRA

Insider	Tipo	Cambio	Precio	Transacción	Presentación
Sachdev Amit	COMPRA	+8,251	Not reported	07/21/2026	07/23/2026
Tatsis Ourania	COMPRA	+8,251	Not reported	07/21/2026	07/23/2026
Garber Alan M	COMPRA	—	Not reported	07/15/2026	07/17/2026
SACHS BRUCE I	COMPRA	—	Not reported	07/15/2026	07/17/2026
McKechnie Duncan	VENTA	-1,541	$519.00	07/02/2026	07/07/2026
Tatsis Ourania	VENTA	-1,500	$524.99	07/02/2026	07/07/2026
Liu Joy	VENTA	-828	$502.71	07/01/2026	07/06/2026
Bozic Carmen	VENTA	-596	$482.50	06/26/2026	06/30/2026
Bozic Carmen	VENTA	-1,020	$462.17	06/18/2026	06/23/2026
Bozic Carmen	VENTA	-4,062	$450.00	06/15/2026	06/17/2026
Bozic Carmen	VENTA	-1,745	$450.00	06/05/2026	06/09/2026
Bozic Carmen	VENTA	-1,974	$450.00	05/29/2026	06/02/2026
Bozic Carmen	VENTA	-1,354	$453.45	05/15/2026	05/19/2026
Bunnage Mark E.	VENTA	-33	$453.45	05/15/2026	05/19/2026
Bozic Carmen	VENTA	-6,988	$450.00	05/12/2026	05/14/2026
Bhatia Sangeeta N.	VENTA	-318	$423.73	05/04/2026	05/05/2026
Bhatia Sangeeta N.	COMPRA	+943	Not reported	05/01/2026	05/05/2026
CARNEY LLOYD	COMPRA	+2,866	$424.45	05/01/2026	05/05/2026
Garber Alan M	COMPRA	+1,433	$424.45	05/01/2026	05/05/2026
Garber Alan M	COMPRA	+472	Not reported	05/01/2026	05/05/2026

Sobre la compañía

Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene. Additionally, they provide TRIKAFTA for individuals with CF aged six years and older who possess at least one F508del mutation. Beyond its established CF therapies, Vertex maintains a robust and diverse clinical pipeline. This includes VX-864, currently in Phase 2 for alpha-1 antitrypsin (AAT) deficiency; VX-147, also in Phase 2, addressing APOL1-mediated focal segmental glomerulosclerosis (FSGS) and other serious kidney conditions; VX-880, a potential treatment for Type 1 Diabetes undergoing Phase 1/2 trials; VX-548, a NaV1.8 inhibitor in Phase 2 for various forms of acute, neuropathic, and musculoskeletal pain; and CTX001, which is in Phase 3 development for severe sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). The company distributes its pharmaceutical products through specialty pharmacies and distributors across the United States, while international sales are facilitated via a network of specialty distributors, retail chains, hospitals, and clinics. Vertex also engages in numerous strategic collaborations with partners such as Affinia Therapeutics, Arbor Biotechnologies, CRISPR Therapeutics, Kymera Therapeutics, Mammoth Biosciences, Moderna, Obsidian Therapeutics, Skyhawk Therapeutics, Ribometrix, Genomics plc, Merck KGaA, and X-Chem. Established in 1989, Vertex Pharmaceuticals is headquartered in Boston, Massachusetts.

Fuente - Link

Competidores

ARGX BMY CVS GSK HCA MCK MDT REGN SNY SYK

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

📰

Vertex Appoints Daniel Brennan to its Board of Directors

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Daniel Brennan has been appointed to its Board of Directors as an independent director. Mr. Brennan has more than 35 years of experience in finance roles at leading healthcare companies, including more than 25 years at Boston Scientific Corporation, a medical device and healthcare technology company. Mr. Brennan retired last year from serving as Boston Scientific's Executive Vice President, Chief Fi.

Business Wire

3,678 Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Banque Pictet & Cie SA

Banque Pictet and Cie SA trimmed its stake in Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 15.7% in the quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 19,818 shares of the pharmaceutical company's stock after selling 3,678 shares during the period.

Defense World

Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Zacks Investment Research

Vertex Pharmaceuticals (VRTX) Rises Higher Than Market: Key Facts

Vertex Pharmaceuticals (VRTX) reached $508.75 at the closing of the latest trading day, reflecting a +2.06% change compared to its last close.

Zacks Investment Research

Forget Cystic Fibrosis: Vertex's Next Growth Engine Could Be Hormone Disorders

Thanks to its most recent acquisition, Vertex now has some promising products in the field of hormone disorders. These could eventually become meaningful growth drivers for the company.

The Motley Fool

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-05-04	4.24	4.47	0.23
2026-02-12	5.11	5.03	-0.08
2025-11-03	4.57	4.8	0.23
2025-08-04	4.29	4.52	0.23
2025-05-05	4.25	4.06	-0.19
2025-02-10	4.02	3.98	-0.04
2024-11-04	4.14	4.38	0.24
2024-08-01	-11.63	-12.83	-1.2
2024-05-06	4.06	4.76	0.7
2024-02-05	4.1	4.2	0.1
2023-11-06	3.97	4.08	0.11
2023-08-01	3.88	3.89	0.01